Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 17
4 116
3 131
2 41
1 23
NEB 4
Curative setting
A 46
C 3
NEB 1
ESMO-MCBS Scores by tumour type
Non-curative setting
Breast Cancer 38
Central Nervous System Malignancies 0
Endocrine Tumours 20
Gastrointestinal Cancers 62
Genitourinary Cancers 60
Gynaecological Malignancies 34
Head and neck cancer 12
Refractory NTRK fusion-positive cancers 2
Sarcoma 9
Skin Cancers 27
TMB-H solid tumours 1
Thoracic Malignancies 66
dMMR/MSI-H solid tumour 1
Curative setting
Breast Cancer 8
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 15
Genitourinary Cancers 3
Gynaecological Malignancies 0
Head and neck cancer 1
Refractory NTRK fusion-positive cancers 0
Sarcoma 2
Skin Cancers 12
TMB-H solid tumours 0
Thoracic Malignancies 4
dMMR/MSI-H solid tumour 0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Durvalumab Etoposide and either carboplatin or cisplatin Platinum-etoposide First-line treatment of extensive-stage SCLC CASPIAN
    Thoracic Malignancies
    		 Small-cell Lung Cancer - CASPIAN

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      3
    Brigatinib - Crizotinib Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor ALTA-1L
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ALK+ ALTA-1L

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      4
    Niraparib - Placebo Maintenance treatment for advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy PRIMA/ENGOT-OV26/COG-3012
    Gynaecological Malignancies
    		 Ovarian, fallopian tubes and peritoneum cancer - PRIMA/ENGOT-OV26/COG-3012

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Atezolizumab Bevacizumab Sorafenib Advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy IMbrave150
    Gastrointestinal Cancers
    		 Hepatobiliary Cancers - Hepatocellular Carcinoma - IMbrave150

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      5
    Olaparib - Enzalutamide or abiraterone (crossover allowed) Treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent PROfound
    Genitourinary Cancers
    		 Prostate cancer Patients with ≥1 alteration in BRCA1, BRCA2 or ATM PROfound

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      3
    Olaparib Bevacizumab Placebo plus bevacizumab Maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability PAOLA-1
    Gynaecological Malignancies
    		 High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer HRD+ BRCA mutation PAOLA-1

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Selpercatinib - Single arm Treatment of adults with RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and/or lenvatinib LIBRETTO-001 (Cohort 1)
    Endocrine Tumours
    		 Thyroid cancer - differentiated RET fusion-positive LIBRETTO-001 (Cohort 1)

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Encorafenib Cetuximab Either irinotecan or FOLFIRI with cetuximab In combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy BEACON CRC
    Gastrointestinal Cancers
    		 Colorectal Cancer BRAF V600E BEACON CRC

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Avelumab Best supportive care Best supportive care First-line maintenance treatment of adult patients who are progression-free following platinum-based ChT JAVELIN Bladder 100
    Genitourinary Cancers
    		 Urothelial Carcinoma - JAVELIN Bladder 100

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Lurbinectedin - Single arm Metastatic SCLC with disease progression on or after platinum-based ChT PM1183-B-005-14
    Thoracic Malignancies
    		 Small-cell Lung Cancer - PM1183-B-005-14

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      2
    Nivo/Ipi (nivolumab and ipilimumab) - Chemotherapy First-line treatment for patients with mNSCLC expressing PD-L1 (≥1%) with no EGFR or ALK genomic tumour aberrations CheckMate 227
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer PD-L1 ≥1% CheckMate 227

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Selpercatinib - Single arm Treatment for adult patients who require systemic therapy following prior treatment with immunotherapy and/or platinum-based ChT LIBRETTO-001
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer RET fusion-positive LIBRETTO-001

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Sacituzumab govitecan-hziy - Single arm (Phase I/II) Treatment for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease IMMU-132-01
    Breast Cancer
    		 Breast Cancer Triple-negative IMMU-132-01

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      2
    Neratinib Capecitabine Lapatinib plus capecitabine Treatment of HER2-positive breast cancer patients who have received two or more prior anti-HER2 based regimens in the metastatic setting NALA
    Breast Cancer
    		 Breast Cancer HER2+ NALA

    1

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      1
    Selpercatinib - Single arm Treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC) LIBRETTO-001 (Cohort 3)
    Endocrine Tumours
    		 Thyroid Cancer - medullary RET-mutant LIBRETTO-001 (Cohort 3)

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Selpercatinib - Single arm As monotherapy for the treatment of adult and adolescents ≥12 years of age with advanced RET-mutant medullary thyroid cancer (MTC) LIBRETTO-001 (Cohort 4)
    Endocrine Tumours
    		 Thyroid Cancer - medullary RET-mutant LIBRETTO-001 (Cohort 4)

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Ripretinib - Placebo (Crossover allowed) Treatment for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib INVICTUS
    Sarcoma
    		 GIST - INVICTUS

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Nivolumab - Taxane ChT docetaxel or paclitaxel Recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine and platinum-based ChT ATTRACTION-3
    Gastrointestinal Cancers
    		 Oesophageal Cancer - ATTRACTION-3

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Rucaparib - Single arm (Phase II) BRCA mutation associated mCRPC previously treated with androgen receptor-directed therapy and a taxane-based ChT TRITON2
    Genitourinary Cancers
    		 Prostate cancer BRCA mutation TRITON2

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pemigatinib - Single arm (Phase II) Cholangiocarcinoma with a FGFR2 fusion or rearrangement that has progressed after at least one prior line of systemic therapy FIGHT-202
    Gastrointestinal Cancers
    		 Cholangiocarcinoma FGFR2 gene fusion or rearrangement FIGHT-202

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Atezolizumab Cobimetinib and vemurafenib Placebo Treatment for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma IMspire150
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600 IMspire150

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Capmatinib - Single arm Treatment of adult patients with advanced non-small cell lung cancer harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy GEOMETRY mono-1
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer METex14 skipping GEOMETRY mono-1

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Capmatinib - Single arm For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping  GEOMETRY mono-1
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer METex14 skipping GEOMETRY mono-1

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Atezolizumab - Platinum-based chemotherapy First-line treatment of patients with high PD-L1 expression ≥50% TC or ≥10% IC and who do not have EGFR mutant or ALK-positive NSCLC IMpower110
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer PD-L1 expression ≥50% TC or ≥10% IC IMpower110

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      5
    Pembrolizumab ChT Placebo plus ChT Treatment of locally recurrent unresectable or metastaticTNBC in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy KEYNOTE-355
    Breast Cancer
    		 Breast Cancer Triple-negative, PD-L1 (CPS ≥10) KEYNOTE-355

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Nivolumab - Single arm (Phase II) Treatment after failure of prior platinum-containing therapy CheckMate 275
    Genitourinary Cancers
    		 Urothelial Carcinoma - CheckMate 275

    1

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      1
    Osimertinib - Placebo Adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations ADAURA
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR exon 19 deletions or exon 21 (L858R) mutation ADAURA

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    Margetuximab ChT Trastuzumab plus ChT Treatment of adult patients who have received two or more prior anti-HER2 regimes, at least one of which was for metastatic disease SOPHIA
    Breast Cancer
    		 Breast Cancer HER2+ SOPHIA

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      2
    Trastuzumab deruxtecan - ChT (irinitecan or paclitaxel) Treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma in patients who have received a prior trastuzumab-based regimen DESTINY-Gastric01
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction adenocarcinoma HER2+ DESTINY-Gastric01

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Trabectedin - Dacarbazine Treatment for patients with advanced soft-issue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients
    Sarcoma
    		 Soft tissue - Liposarcoma or leiomyosarcoma - -

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      2

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.